Full-Time

Principal Quality Engineer

Shockwave Medical

Posted on 9/6/2025

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$114k - $197.8k/yr

+ Long-term Incentive Program

Santa Clara, CA, USA

In Person

Category
QA & Testing (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor of Science degree in Engineering. Master’s Degree is preferred.
  • 10+ years of hands-on experience working as an engineer in the Medical Device industry.
  • Working knowledge of applicable medical device regulations such as ISO 13485, ISO 14971, ISO 11137, ISO 10993, 21 CFR Part 820, MDD 93/42/EEC, EU MDR, and MDSAP required.
  • Ability to perform multiple tasks concurrently with accuracy.
  • Ability to understand regulatory implications of Design Changes.
  • Must have demonstrated hands-on experience in: Design Verification and Validation, Hazard/Risk Analysis, Design/Usability/Process FMEA, Reliability and Stability Testing, FDA Good Manufacturing Practices (GMP).
  • Clear and effective communication skills
  • Proficiency in MS Word, Excel and Power Point required
  • High attention to detail and accuracy is required
  • Ability to work in a fast-paced environment while managing multiple priorities.
  • Employee may be required to lift objects up to 25lbs.
Responsibilities
  • Actively participate in Design Control activities such as: Ensure new Design projects and Design Change activities are performed in compliance with Design Control procedure and relevant regulatory/user requirements.
  • Design reviews to document and ensure that the design meets the intended customer requirements.
  • Draft Design Verification and Validation Test Protocols, Methods and Reports.
  • Subject Matter Expert on application of relevant standards, test sample sizes and usage of statistical techniques for new Design and Development Projects.
  • Lead and responsible for ongoing management of Risk Analysis, Failure Mode and Effects Analysis (FMEA), Fault Tree Analysis (FTA.), Risk Management Plans and Reports.
  • Perform periodic review and update of Post Market Surveillance data to ensure it is aligned with Product Risk Management Files.
  • Oversee Design Verification and Validation Testing.
  • Lead/coordinate/perform verification/ validation activities for: Biocompatibility Testing, Packaging Validation, Accelerated and Real Time Shelf-Life/Aging Studies, Sterilization Validation, Test Method Validation.
  • Identify testing and analysis required for the finished device to ensure conformance to product and user specifications.
  • Develop device Quality Plans to ensure that the elements of the Quality Management System are appropriately described and managed.
  • Audit DHFs to ensure compliance with Design Control procedure.
  • Provide support to Manufacturing and Operations: Perform or assist in root cause analysis of product non-conformances found in manufacturing, Assist in qualifying molds, fixtures, tooling, and equipment, Perform/support process validations, Identify, drive, and implement process improvements, Participate in Supplier Quality activities including material non-conformances and Supplier audits, Work with contract manufacturers to maintain product quality and resolve any non-conformances that arise, Recommend QC sampling plans based on desired confidence and reliability limits.
  • Evaluate/investigate and document investigation results for returned devices from clinical studies and commercial complaints.
  • Review, investigate, disposition, and drive to completion Non-conforming Reports (NCR), Audit Findings and Corrective and Preventive Actions (CAPA.)
  • Analyze and review data for key Quality metrics to identify any significant trends.
  • Initiate, review, and approve Document Change Orders (DCO.)
  • Drive Standard Gaps Assessment activities.
  • Participate in internal, supplier and third-party audits (FDA, FDB, Notified Body, etc.)
  • Support ongoing Regulatory submission activities and product approval processes.
  • Participate in the implementation and continuous improvement of the Quality Management System.
  • Provide technical support to the Quality inspection group.
Desired Qualifications
  • Experience with Software and Hardware Validations is a plus.
  • Working knowledge of IEC 62304, IEC 62366 and IEC 60601 is preferred.
  • Experience and involvement with complaint investigations, including MDRs and Vigilance Reporting is preferred.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE